SNOA Sonoma Pharmaceuticals, Inc.

CIK 0001367083 50 ready 8-Ks latest August 19, 2026, 5:27 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 19, 2026, 5:27 PM ET

Top materiality 0.75

Event mix other_material ×30 · other ×11 · leadership ×7

Sentiment 7 pos · 4 neg · 39 neu

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for SNOA

Highest-materiality recent filing

Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US

April 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 9.01 ◈ Material Agreements

Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
Term includes two optional one-year renewals upon mutual written agreement.

Read filing →

August 19, 2026, 5:27 PM ET other materiality 0.15 neutral item 5.07

Sonoma Pharmaceuticals special meeting cancelled after quorum not achieved

Adjourned special meeting on Aug 19, 2026 cancelled; no quorum (1,157,852 of 3,473,554 shares needed).
June 18, 2026, 4:33 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals ups ATM offering capacity to $3.64M

Sold 173,073 shares for $574,633 since Sept 2025 under existing ATM agreement.
April 30, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Sonoma Pharmaceuticals prices $4.0M public offering of units at $1.35/unit

Offering of 2,962,962 units initially, each unit one share (or pre-funded warrant) and one warrant at $1.35 per unit.
April 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 9.01 ◈ Material Agreements

Sonoma Pharmaceuticals enters manufacturing supply agreement with Kenvue for Microcyn products in US

Agreement with Kenvue Brands LLC for US sale of Microcyn-based products, effective Oct 24, 2025 through March 2027.
January 28, 2026, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Sonoma Pharmaceuticals appoints Vanessa Jacoby to board; Birnbaum retires as director

Dr. Jay Birnbaum retired from board Jan 28, 2026; will serve as consultant for one year, receiving 5,000 RSUs per quarter.
January 12, 2026, 6:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files updated investor presentation; no specific financial or operational details disclosed

Filing includes an updated investor presentation as of January 2026, furnished as Exhibit 99.1.
January 2, 2026, 6:59 PM ET other materiality 0.25 neutral item 5.02

Sonoma Pharmaceuticals grants annual equity to executives and directors

Non-employee directors each received 10,000 options at $3.68, vesting in 3 equal annual tranches.
October 23, 2025, 7:59 PM ET leadership materiality 0.65 negative item 5.02

Sonoma Pharma terminates EVP/COO Bruce Thornton for cause, effective Oct 18

Bruce Thornton terminated as EVP and Chief Operating Officer on October 18, 2025.
October 9, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 9.01

CEO Amy Trombly amends employment agreement; COO Bruce Thornton retires, position eliminated

CEO Amy Trombly's base salary set at $475,000 per annum; target annual bonus of 50% of base salary.
September 29, 2025, 7:59 PM ET other material materiality 0.10 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files updated investor presentation; no material new details disclosed

Furnished updated investor presentation dated September 29, 2025, under Item 8.01.
September 26, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

Sonoma Pharma enters $2.07M ATM stock offering with Ladenburg Thalmann

At Market Issuance Sales Agreement with Ladenburg Thalmann for up to $2,070,463 of common stock.
August 29, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Sonoma Pharmaceuticals shareholders elect director, approve executive compensation and auditor

Dr. Jay Birnbaum elected Class II director with 123,034 votes for, 19,478 withheld.
April 28, 2025, 7:59 PM ET other materiality 0.20 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files updated investor presentation; no specific new data in excerpt

Company filed an updated investor presentation as of April 28, 2025, under Item 8.01.
April 7, 2025, 7:59 PM ET other materiality 0.10 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals posts updated investor presentation with no material new information

Filed updated investor presentation as of April 7, 2025, under Item 8.01.
March 25, 2025, 7:59 PM ET other material materiality 0.35 positive item 1.01 item 9.01

Sonoma expands Microcyn distribution deal with WellSpring to include additional products

Amendment No. 1 dated March 21, 2025 adds new Microcyn-based products to existing Master Supply Agreement.
January 30, 2025, 6:59 PM ET other material materiality 0.60 positive item 1.01 item 9.01

Sonoma inks exclusive US distribution deal with WellSpring for Microcyn products

Exclusive US distribution agreement with WellSpring Pharmaceutical, effective Jan 29, 2025.
January 3, 2025, 6:59 PM ET other material materiality 0.25 neutral item 5.02

Sonoma Pharma grants 7,500 options to directors and 10,000 RSUs to each top executive

Non-employee directors each received 7,500 options at $2.68, vesting over three years.
November 21, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.02

Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma

EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.
October 22, 2024, 7:59 PM ET other material materiality 0.65 positive item 1.01 item 8.01 item 9.01

Sonoma expands Medline distribution to Canada and OTC retail in US and Canada

Amendment No. 1 to Distribution Agreement with Medline dated Oct 17, 2024 adds Canada and OTC wound care sales to retailers.
September 20, 2024, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files prospectus supplement for existing ATM equity offering with Maxim Group

Company entered Equity Distribution Agreement with Maxim Group on Dec 15, 2023, amended March 8, 2024.
August 28, 2024, 7:59 PM ET other material materiality 0.75 neutral item 5.03 item 5.07 item 7.01 item 9.01

Sonoma Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 29 to maintain Nasdaq listing

Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.
August 23, 2024, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files prospectus supplement for existing at-the-market equity offering

Company entered into Equity Distribution Agreement with Maxim Group LLC on Dec 15, 2023, amended March 8, 2024.
August 21, 2024, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 9.01

Sonoma Pharmaceuticals enters 5-year distribution agreement with Medline for wound care products

Distribution agreement effective August 19, 2024, covers wound cleansers and other products in the United States.
June 27, 2024, 7:59 PM ET other materiality 0.15 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files prospectus supplement for ATM equity facility

Filed a prospectus supplement on June 27, 2024 for at-the-market offering of common stock through Maxim Group LLC.
April 9, 2024, 7:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Sonoma Pharmaceuticals files updated investor presentation highlighting HOCl product portfolio and global reach

Presentation covers stabilized hypochlorous acid products for wound, eye, oral, nasal, and dermatological care.
April 2, 2024, 7:59 PM ET other materiality 0.05 neutral item 7.01 item 9.01

Sonoma Pharmaceuticals updates investor presentation; no material changes

HOCl product portfolio covers wound, eye, oral, nasal, dermatology, podiatry, and animal health
March 22, 2024, 7:59 PM ET regulatory materiality 0.55 negative item 3.01 ◈ Listing & Compliance Notices

Nasdaq grants Sonoma Pharmaceuticals 180-day extension to meet $1.00 bid price rule

Company received until September 16, 2024 to regain compliance with Nasdaq minimum $1.00 closing bid price rule.
March 8, 2024, 6:59 PM ET other material materiality 0.35 neutral item 1.01 item 9.01 ◈ Material Agreements

Sonoma Pharmaceuticals increases ATM offering capacity by $785,679

Amendment No. 1 to Dec 2023 Equity Distribution Agreement with Maxim Group LLC allows sale of up to $785,679 in additional common shares.
January 10, 2024, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Sonoma provides January 2024 investor presentation; no material new financial data

Presentation reiterates stabilized HOCl platform for dermatology, wound, eye, nasal, oral, animal health.
January 9, 2024, 6:59 PM ET other material materiality 0.45 positive item 1.01 item 9.01 ◈ Material Agreements

Sonoma Pharma enters 2-year exclusive EU license for Avenova eye products

Exclusive license to use Avenova marks on Ocudox eye products in EU, effective Jan 5, 2024.
December 29, 2023, 6:59 PM ET other material materiality 0.30 neutral item 5.02

Sonoma Pharmaceuticals grants 180,000 stock options to executive officers at $0.18 per share

CEO Amy Trombly, interim CFO Jerry Dvonch, and COO Bruce Thornton each received 60,000 options.
December 18, 2023, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01 ◈ Material Agreements

Sonoma Pharmaceuticals enters into ATM equity distribution agreement with Maxim Group for up to $392,077

ATM facility allows Sonoma to sell up to $392,077 of common stock through Maxim Group.
October 11, 2023, 7:59 PM ET other materiality 0.10 neutral item 8.01 item 9.01

Sonoma Pharmaceuticals files amended 8-K with updated investor presentation; no material new information

Amended filing corrects item number from original 8-K dated October 11, 2023.
October 11, 2023, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Sonoma Pharmaceuticals provides updated investor presentation; no material changes disclosed

Exhibit 99.1 contains an updated corporate presentation dated October 2023.
September 28, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 item 5.07 ◈ Shareholder Votes ×3◈ Listing & Compliance Notices

Sonoma Pharma receives Nasdaq delisting notice for bid price non-compliance; say-on-pay vote fails

Received Nasdaq notice on Sept 22, 2023 for failure to maintain $1 minimum bid price for 30 consecutive days.
July 14, 2023, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 9.01 ◈ executive_change

Sonoma Pharmaceuticals appoints Controller and sets new interim CFO consulting terms

John Dal Poggetto appointed Controller effective July 17, 2023; annual salary $100,000, bonus up to 20%, option grant for 5,000 shares vesting over three years.
May 10, 2023, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Sonoma Pharmaceuticals files updated investor presentation; no material new information disclosed

Filed Form 8-K with Item 7.01 disclosure attaching an updated investor presentation dated May 10, 2023.
April 13, 2023, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 9.01 ◈ executive_change ×2

Sonoma Pharmaceuticals CFO Chad White resigns; Jerry Dvonch named interim CFO

Chad White resigned as CFO effective April 7, 2023; unvested options forfeited.
February 24, 2023, 6:59 PM ET other material materiality 0.30 neutral item 1.01 item 9.01 ◈ Material Agreements

Sonoma Pharmaceuticals upsizes ATM offering by up to $420,838

Entered amendment to ATM offering agreement with Ladenburg Thalmann on Feb 24, 2023.
January 31, 2023, 6:59 PM ET other material materiality 0.60 positive item 1.01 item 9.01 ◈ Material Agreements

Sonoma enters exclusive South Korea distribution deal with Daewoong for Primocyn

Exclusive distribution agreement effective Jan 26, 2023 for Primocyn Skin Solution (Microcyn technology) in South Korea.
January 6, 2023, 6:59 PM ET other material materiality 0.00 neutral item 7.01 item 9.01

Sonoma Pharmaceuticals updates investor presentation; no material new disclosures

Presentation highlights stabilized hypochlorous acid products for dermatology, wound care, eye care, and other applications.
December 30, 2022, 6:59 PM ET other materiality 0.35 neutral item 5.02 item 9.01

Sonoma Pharmaceuticals grants annual options to execs and directors at $1.08 strike

Board revised Director Compensation Plan, reducing annual director option grants to 20,000 per director.
December 23, 2022, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01 ◈ Material Agreements

Sonoma Pharmaceuticals enters ATM equity offering agreement for up to $2.7M

ATM agreement with Ladenburg Thalmann to sell common stock up to $2,700,000 aggregate gross proceeds.
October 7, 2022, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change ×3

Sonoma Pharmaceuticals appoints Chad White as CFO, succeeding Jerry Dvonch effective Nov 18, 2022

Jerry Dvonch resigns as CFO effective Nov 18, 2022; will assist transition to Boulder, CO office by Dec 31.
September 16, 2022, 7:59 PM ET other material materiality 0.15 negative item 5.07

Sonoma Pharmaceuticals say-on-pay fails; other proposals approved at annual meeting

Jay Birnbaum elected Class II director with 277,332 votes for, 169,061 withheld.
July 22, 2022, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change ×2

Sonoma Pharmaceuticals appoints CEO to board, amends exec agreements, CFO to resign amid office consolidation

CEO Amy Trombly appointed to board effective July 22, 2022; amended employment agreement with severance of one-time base salary.
January 20, 2022, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

Sonoma Pharmaceuticals enters two distribution deals for Microcyn products

Non-exclusive distribution with Salus Medical for Microcyn dental/derm/wound/eye care in US; one-year initial term.
January 14, 2022, 6:59 PM ET other materiality 0.30 neutral item 5.02

Sonoma Pharmaceuticals grants 30,000 stock options each to CEO, CFO, COO and directors

Annual grant of stock options to employees, executive officers, and directors on January 14, 2022.
January 6, 2022, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Sonoma files investor presentation; no new material details visible in exhibit text

Furnished investor presentation under Item 7.01 for virtual conferences on Jan 10-13, 2022.
November 9, 2021, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

Sonoma signs 20-year exclusive license & distribution deal with Dyamed for four Southeast Asian markets

Exclusive rights for hypochlorous acid products (dermatology, eye, oral) in Singapore, Malaysia, Indonesia, and Thailand.